Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€22.38
Change (%) Stock is Down 0.09 (0.40%)
Volume18,638
Data as of 11/24/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
16-Nov-2017Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 16, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Nov. 16, 2017-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.co... 
 Printer Friendly Version
15-Nov-2017ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017. Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017. Will add approximately $19 million in additional gross proceeds for total of $144 million in gross proceeds. ... 
 Printer Friendly Version
14-Nov-2017ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference
LYON, France--(BUSINESS WIRE)--Nov. 14, 2017-- Regulatory News: ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London,... 
 Printer Friendly Version
13-Nov-2017ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
LYON, France--(BUSINESS WIRE)--Nov. 13, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top